Ardent Health Inc

Análisis de la acción Ardent Health Inc (ARDT)

$12.120

+0.446 (+3.68%)Al cierre

Loading chart…
Máximo
12.130
Apertura
11.840
Precio medio ponderado por volumen
12.03
Volumen
343.08K
Capitalización
—
Mínimo
11.840
Importe
4.13M
EV/EBITDA, TTM
8.15

Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.

ardenthealth.com

Análisis de IA of Ardent Health Inc (ARDT)

Comprar

Ardent Health Partners Inc is a good buy right now due to its current price of $11.95, which is below the average analyst price target of $13.67, indicating potential upside. Additionally, the forward P/E ratio of 9.50 suggests the stock is undervalued compared to its earnings potential. However, the main risk is the recent EPS miss of 29.41%, which could affect investor confidence.

Métricas de valoración

El PER previsto actual de Ardent Health Inc (ARDT) es 9.50, frente a su media de 5 años de 8.49.

PER previsto

Valor razonable
Media 5A P/E
8.49
P/E actual
9.50
Sobrevalorada
10.18
Infravalorada
6.81

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
6.96
EV/EBITDA actual
8.15
Sobrevalorada
8.46
Infravalorada
5.45

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.28
P/S actual
0.25
Sobrevalorada
0.37
Infravalorada
0.20

Ballenas con ARDT en cartera

G

GoldenTree Asset Management LP

+ Con en carteraARDT

-5.28%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-29 (ET)

16:30:00

University of Kansas Health System Acquires St. Francis Campus

2026-09-02 (ET)

08:30:00

Ardent Health Expands Medical Services with UT Health East Texas Partnership

2026-08-04 (ET)

16:30:00

Ardent Health Reports Q2 Revenue of $1.62B

16:30:00

Company Confirms FY26 Revenue Outlook of $6.4B to $6.7B

2026-06-03 (ET)

09:40:00

Morgan Stanley Maintains Equal Weight Rating on Ardent Health with $12 Price Target

Noticias

Preguntas frecuentes sobre ARDT, respondidas por Alphio AI

Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings. It operates in the Healthcare sector.

Ardent Health Partners Inc is a good buy right now due to its current price of $11.95, which is below the average analyst price target of $13.67, indicating potential upside. Additionally, the forward P/E ratio of 9.50 suggests the stock is undervalued compared to its earnings potential. However, the main risk is the recent EPS miss of 29.41%, which could affect investor confidence.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar